
    
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group,
      three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening
      / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration
      Period), and a 2-week Safety Follow-Up Period
    
  